Back

A mixture of essential oils from three Cretan Aromatic Plants (thyme, Greek sage and Cretan dittany, CAPeo) inhibits SASR-CoV-2 proliferation: in vitro evidence and a Proof-of-Concept intervention study in mild ambulatory COVID-19-positive patients

Lionis, C.; Karakasiliotis, I.; Petelos, E.; Linardakis, M.; Diamantakis, A.; Symvoulakis, E.; Panopoulou, M.; Kampa, M.; Pirintsos, S. A.; Sourvinos, G.; Castanas, E.

2021-01-15 pharmacology and therapeutics
10.1101/2021.01.11.20248947 medRxiv
Show abstract

The need for therapeutic regimens for the non-critically ill patients of the COVID-19 pandemic remains unmet. In this line, repurposing existing drugs, against known or predicted SARS-CoV-2 protein actions, has been advanced, while natural products have also been tested. Previous work has shown that a Cretan Aromatic Plant (Thymbra capitata (L.) Cav., Salvia fruticosa Mill. and Origanum dictamnus L.) essential oil mixture (CAPeo) has a remarkable in vitro antiviral activity against Influenza A & B and Rhinovirus 14 strains, decreasing the symptoms of upper respiratory tract infections, while proven safe in experimental animals and humans. Here, we tested CAPeo in VERO cells infected with SASR-CoV-2. We report that this mixture, at similar concentrations as those previously reported, exhibits a remarkable antiviral activity. Administration of 1 ml of a 1.5% CAPeo in olive oil, in a Proof-of-Concept intervention study in SARS-CoV-2-positive, exhibiting mild COVID-19 symptoms, humans resulted in a significant amelioration of general and local symptoms of the disease. We conclude that CAPeo may be a valuable addition for the prevention and/or treatment of mild COVID-19 ambulatory patients, pending a confirmation through a prospective randomized controlled trial in humans (NCT04705753).

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Frontiers in Pharmacology
111 papers in training set
Top 0.1%
27.2%
2
Frontiers in Medicine
120 papers in training set
Top 0.1%
13.0%
3
Pharmaceuticals
34 papers in training set
Top 0.1%
11.3%
50% of probability mass above
4
Scientific Reports
3612 papers in training set
Top 12%
6.4%
5
PLOS ONE
5266 papers in training set
Top 40%
2.7%
6
Microorganisms
106 papers in training set
Top 0.9%
2.5%
7
PeerJ
308 papers in training set
Top 3%
2.4%
8
eLife
5828 papers in training set
Top 43%
2.2%
9
Viruses
332 papers in training set
Top 2%
2.0%
10
Journal of Clinical Medicine
97 papers in training set
Top 2%
1.8%
11
International Journal of Infectious Diseases
129 papers in training set
Top 2%
1.5%
12
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 1%
1.5%
13
Pharmaceutics
24 papers in training set
Top 0.4%
1.5%
14
Genes
144 papers in training set
Top 3%
1.2%
15
Journal of Extracellular Vesicles
55 papers in training set
Top 0.4%
1.2%
16
eClinicalMedicine
77 papers in training set
Top 1%
1.2%
17
Heliyon
152 papers in training set
Top 6%
1.0%
18
Contemporary Clinical Trials Communications
11 papers in training set
Top 0.5%
0.9%
19
Pathogens
56 papers in training set
Top 1%
0.9%
20
Virus Research
37 papers in training set
Top 0.7%
0.9%
21
Cureus
68 papers in training set
Top 4%
0.9%
22
Life
29 papers in training set
Top 0.8%
0.9%
23
Frontiers in Microbiology
427 papers in training set
Top 8%
0.9%
24
BMC Infectious Diseases
133 papers in training set
Top 4%
0.9%
25
Schizophrenia
21 papers in training set
Top 0.4%
0.9%
26
Frontiers in Virology
15 papers in training set
Top 0.2%
0.9%
27
International Journal of Molecular Sciences
494 papers in training set
Top 17%
0.6%
28
Emerging Microbes & Infections
74 papers in training set
Top 1%
0.6%
29
British Journal of Clinical Pharmacology
21 papers in training set
Top 0.5%
0.6%
30
The American Journal of Tropical Medicine and Hygiene
68 papers in training set
Top 2%
0.6%